President Cyril Ramaphosa visited the FuturePharma facility at CSIR in Pretoria as South Africa takes steps to strengthen domestic medicine production and decrease reliance on imported supplies.
The country is intensifying efforts to produce pharmaceutical ingredients and medicines locally, aiming to lessen import dependency and enhance its capacity to provide critical medical supplies during future healthcare crises.
During his visit to the FuturePharma facility at CSIR in Pretoria, President Cyril Ramaphosa was accompanied by the Minister of Science, Technology and Innovation, Professor Blade Nzimande, and the Minister of Health, Dr. Aaron Motsoaledi.
This facility is designed to bolster South Africa's capabilities in pharmaceutical manufacturing, assisting researchers and innovators in transitioning promising technologies from laboratory settings to large-scale production and commercialization.
South Africa's Goals for Reducing Drug Import Dependence
A key focus of FuturePharma will be supporting the local production of active pharmaceutical ingredients (APIs) and medicines. This will help mitigate South Africa's vulnerability to disruptions in international pharmaceutical supply chains.
The Government Communications and Information System (GCIS) reported that the facility will promote local production of APIs and medicines, thereby reducing import reliance and strengthening supply security.
The shift towards broader domestic production aims to give South Africa stronger control over the availability of vital medications while simultaneously developing local pharmaceutical potential.
Furthermore, FuturePharma is expected to provide infrastructure and technical expertise for researchers, innovators, and companies involved in pharmaceutical technology development.
Translating Research from Labs to Production
According to GCIS, one of the main objectives of the facility is to bridge the gap between scientific discoveries and commercially viable drugs or pharmaceutical technologies.
GCIS specified that the facility's goal is to connect promising laboratory research with the development, scaling, and commercialization of pharmaceutical technologies.
The facility will provide researchers, innovators, and industry partners with access to specialized infrastructure and knowledge to advance technologies to production, supporting technology transfer and skills development.
This means that pharmaceutical innovations created by scientists can receive the necessary technical support and infrastructure to move from experimental laboratory stages to production.
Building Capacity for the Next Health Emergency
This facility is also expected to be part of South Africa's preparation for future pandemics and other major public health crises.
The Covid-19 pandemic highlighted the risks faced by countries heavily dependent on international supply chains for medicines, vaccines, and other essential health products.
GCIS noted that FuturePharma 'will contribute to South Africa's preparedness for future pandemics and health crises by strengthening local pharmaceutical capabilities.'